期刊文献+

壳聚糖-小干扰RNA下调C6细胞多药耐药相关蛋白1表达的研究

The chitosan-small interfering RNA suppressed the expression levels of multidrug resistant-associated protein 1 in C6 cells
原文传递
导出
摘要 目的 探讨具有最大转染效率和沉默效应时壳聚糖-小干扰RNA (siRNA)的壳聚糖与siRNA(NP)比值.方法 用激光粒度仪测定壳聚糖-siRNA纳米颗粒的直径和Zeta电位.荧光标记的siRNA转染到C6细胞并初步鉴定转染效率.分6组进行转染:分别加入不同NP比值的壳聚糖-siRNA(实验组)、LipofectamineTM 2000和多药耐药相关蛋白1(MRPl) siRNA(阳性对照组)、壳聚糖-阴性对照siRNA纳米粒(阴性对照组)和空白壳聚糖纳米粒(空白组),采用逆转录-聚合酶链反应(RT-PCR)和Western blot法检测MRPl mRNA和蛋白水平的表达.结果 成功制备了壳聚糖-siRNA纳米粒的直径和电位分别是186.7 nm和18.57 mV、209.5 nm和13.52 mV、492.3 nm和48.58 mV.其中NP比值为175时纳米颗粒对目的蛋白的表达量可以下调到(23.2±4.3)%.结论 壳聚糖-siRNA的NP比值为175时可以有效抑制MRP1基因和蛋白的表达. Objective To investigate the chitosan-small interfering RNA (siRNA) NP ratio with maximum transfection efficiency and silence effect.Methods The diameter and Zeta potential of the chitosan-siRNA nanoparticles were measured by using laser particle size analyzer.Fluorescent-labeled siRNA was transfected into C6 cells for preliminary appraisal transfection efficiency.The transfected C6 cells were divided into 6 groups:three experimental groups,which were transfected with chitosan-siRNA nanoparticle ratio of 175∶ 1,88∶1 and 44∶ 1,the positive control group,which was transfected with multidrug resistantassociated protein 1 (MRP1)-siRNA by LipofectamineTM 2000 and MRP1 siRNA; the negative control group,which was transfected with chitosan-negative control siRNA nanoparticles,and the blank group,which was transfected with blank chitosan-nanoparticles.The expression levels of MRP1 mRNA and protein in C6 cells were assessed by using reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting respectively.Results The chitosan-siRNA nanoparticles were successfully prepared.With decreases in NP ratio,the chitosan-siRNA nanoparticles had the diameters of 186.7 nm,209.5 nm,and 492.3 am,and the potentials were 18.57 mV,13.52 mV,and 48.58 mV,respectively.Target protein expression could be down-regulated to (23.2 ± 4.3)% when the NP ratio of nanoparticles was 175.Conclusion In C6 cells,MRP1 can be effectively suppressed when the chitosan-siRNA ratio was 175∶ 1.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2013年第9期1861-1863,共3页 Chinese Journal of Experimental Surgery
基金 湖北省卫生厅青年科技人才基金资助项目(131534)
关键词 壳聚糖 小干扰RNA 多药耐药相关蛋白1 Chitosan Small interfering RNA Multidrug resistant-associated protein 1
  • 相关文献

参考文献3

二级参考文献12

  • 1尤永平,常津,傅震,刘宁,浦佩玉.超微载体介导反义端粒酶RNA抑制胶质瘤细胞生长的研究[J].中华实验外科杂志,2004,21(11):1296-1297. 被引量:5
  • 2金化民 钱辉军 张重.大鼠经皮心脏穿刺取血法[J].中华实验外科杂志,1997,14:167-168.
  • 3Yang LY, Trujillo JM . Biological characterization of multi- drug resistant human colon carcinoma sublines induced/ selected by two methods[J]. Cancer Res, 1990, 50(6): 3218- 3225.
  • 4Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, ceL- lular, and pharmacological aspects of the multidrug trans- porter [J]. Annu Rev Pharmacol Toxicol, 1999, 39(8): 361- 398.
  • 5Krishna R, Mayer LD. Multidrug resistance (MDR) in can- cer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs [J]. Eur J Pharm Sci, 2000, 11(4): 265- 283.
  • 6Ling V. Muhidrug resistance: molecular mechanisms and clinical relevance. [J]. Cancer Chemother Pharmcol, 1997, 40 (Suppl): S3-8.
  • 7Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance associated protein MRP [J]. Eur J Cancer, 1996, 32A(6): 945-957.
  • 8Daschner PJ, Ciolino HP, Plouzek CK, et al. Increased AP-I activity in drug resistant human breast cancer MCF-7 cells [J]. Breast Cancer Res Treat, 1999, 53(3): 229-240.
  • 9Cole SP, Bhardwaj G, Gerlach JH, et al. Over-expression of a transporter gene in a muhidrug-resistant human lung cancer cell line [J]. Science, 1992, 258(5088): 1650-1654.
  • 10Ishikawa T, Li ZS, Lu YP. The GS-X pump in plant, yeast, and animal ceils: structure, function, and gene expression [J]. Biosci Rep, 1997, 17(2): 159-207.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部